.
het@alligatorbioscience.com
Sitemap
 
 
 
.
 
 
 
 
Scientific Advisors

 



Professor Thomas Tötterman, Clinical Immunology Division, Department of Immunology, Genetics & Pathology, Uppsala University, is an internationally recognized pioneer in the field of cancer immunotherapy. Alligator Bioscience has an extensive scientific collaboration with Professor Tötterman and his group that has led to the development of the IMCAN (IMmunotherapy of CANcer) concept for local immunotherapy of cancer. The Alligator pipeline has two projects within the IMCAN concept, ADC-1013 and ADC-1015, and Professor Tötterman is now involved in the pre-clinical development of these two projects. Thomas Tötterman received his MD from the University of Helsinki, 1975 and his PhD from the same University 1978. He was appointed Professor/Senior Consultant in Clinical Immunology 1995 and was President for the Swedish Society of Gene and Cell Therapy (SSGCT) 2006-2010. Thomas Tötterman has been Initiator/Sponsor of two academic phase I/II trials, “first-in-man”, studies with immunomodulatory drug candidates. He has published more than 170 peer-reviewed scientific papers including several reviews.


 





Karl Olof Borg
Former member of the Board of Alligator Bioscience. PhD in Pharmaceutical Sciences.
Previously Chief Scientific Officer and Vice President of Active Biotech AB.
More than 25 years of experience from leading positions in the pharmaceutical industry including Astra,
Pharmacia and Ferring.

 

 

 

 

 
Print
 
 
 
 
 
 
 
 
Alligator bioscience